Difference between revisions of "Olympus Corporation- Company Profile"

From DolceraWiki
Jump to: navigation, search
(Projections for FY 2012)
(Organisation Structure)
 
(27 intermediate revisions by 2 users not shown)
Line 2: Line 2:
  
 
OLYMPUS CORPORATION, a Japan-based manufacturer, mainly manufactures and sells medical products, life and industrial products, imaging products, information communication products and other products. The Company operates in five business segments.  
 
OLYMPUS CORPORATION, a Japan-based manufacturer, mainly manufactures and sells medical products, life and industrial products, imaging products, information communication products and other products. The Company operates in five business segments.  
* The Medical segment is engaged in the manufacture and sale of medical endoscopes, surgical endoscopes, endoscope disposal equipment and ultrasonic endoscopes.
+
* '''Medical Systems:''' Manufacture and sale of medical endoscopes, surgical endoscopes, endoscope disposal equipment and ultrasonic endoscopes
* The Life and Industrial segment provides biological microscopes, industrial microscopes, endoscopes for industrial use and non-destructive testing equipment.
+
* '''Life and Industrial:''' Provides biological microscopes, industrial microscopes, endoscopes for industrial use and non-destructive testing equipment
* The Imaging segment is engaged in the manufacture and sale of digital cameras and voice recorders.
+
* '''Imaging:''' Manufacture and sale of digital cameras and voice recorders
* The Information Communication segment is engaged in the sale of mobile terminals, such as cellular phones.
+
* '''Information Communication:''' Sale of mobile terminals, such as cellular phones  
* The Others segment is engaged in the development of biomaterials and systems, industrial endoscopes, nondestructive inspection equipment, printers, mobile solutions and mobile contents services, the development and sale of package software, the sale of semiconductor-related equipment and electronic machines, as well as the development of systems.
+
* '''Others:''' Development of biomaterials and systems, industrial endoscopes, nondestructive inspection equipment, printers, mobile solutions and mobile contents services, the development and sale of package software, the sale of semiconductor-related equipment and electronic machines, as well as the development of systems
  
 
<br>
 
<br>
Line 14: Line 14:
 
===Key Facts===
 
===Key Facts===
 
{|border="2" cellspacing="0" cellpadding="4" width="54%" align="center"
 
{|border="2" cellspacing="0" cellpadding="4" width="54%" align="center"
|bgcolor = "#DBE5F1"|'''Established'''
+
|bgcolor = "#95B3D7"|'''Established'''
 
|1919
 
|1919
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Headquarters'''
+
|bgcolor = "#95B3D7"|'''Headquarters'''
 
|Tokyo, Japan
 
|Tokyo, Japan
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Type'''
+
|bgcolor = "#95B3D7"|'''Type'''
 
|Public Company
 
|Public Company
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Website'''
+
|bgcolor = "#95B3D7"|'''Website'''
 
|[http://www.olympus-global.com/en/ www.olympus-global.com]
 
|[http://www.olympus-global.com/en/ www.olympus-global.com]
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Regional involvement'''
+
|bgcolor = "#95B3D7"|'''Regional involvement'''
 
|Worldwide
 
|Worldwide
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Business lines'''
+
|bgcolor = "#95B3D7"|'''Business lines'''
 
|Manufacture and Sales of precision machinery and instruments  
 
|Manufacture and Sales of precision machinery and instruments  
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Employees'''
+
|bgcolor = "#95B3D7"|'''Employees'''
 
|34,391<br> Medical System Business: 15,000 Approx.
 
|34,391<br> Medical System Business: 15,000 Approx.
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Group Companies'''
+
|bgcolor = "#95B3D7"|'''Group Companies'''
 
|Approx. 180 Subsidiaries
 
|Approx. 180 Subsidiaries
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Chairman & CEO'''
+
|bgcolor = "#95B3D7"|'''Chairman & CEO'''
 
|Tsuyoshi Kikukawa
 
|Tsuyoshi Kikukawa
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''President & COO'''
+
|bgcolor = "#95B3D7"|'''President & COO'''
 
|Michael C. Woodford
 
|Michael C. Woodford
 
|-
 
|-
|bgcolor = "#DBE5F1"|'''Consolidated Net Sales (2011)'''
+
|bgcolor = "#95B3D7"|'''Consolidated Net Sales (2011)'''
 
|847.1 Billion YEN
 
|847.1 Billion YEN
 
|}
 
|}
Line 59: Line 59:
 
|-
 
|-
 
|align = "center" rowspan = "2"|'''Revenue'''
 
|align = "center" rowspan = "2"|'''Revenue'''
|2011: ¥847.10B / $10.58B
+
|2011: ¥ 847.10 B / $ 10.58 B
 
|-
 
|-
|2010: ¥ 883.08B / $11.03B
+
|2010: ¥ 883.08 B / $ 11.03 B
 
|-
 
|-
 
|align = "center" bgcolor = "#DBE5F1"|Revenue Change
 
|align = "center" bgcolor = "#DBE5F1"|Revenue Change
Line 67: Line 67:
 
|-
 
|-
 
|align = "center" rowspan = "2"|'''Operating Income'''
 
|align = "center" rowspan = "2"|'''Operating Income'''
|2011: ¥35.4 B / $442M
+
|2011: ¥ 35.4 B / $ 442 M
 
|-
 
|-
|2010: ¥60.1B / $751M
+
|2010: ¥ 60.1 B / $ 751 M
 
|-
 
|-
 
|align = "center" bgcolor = "#DBE5F1"|Operating Income Change
 
|align = "center" bgcolor = "#DBE5F1"|Operating Income Change
Line 75: Line 75:
 
|-
 
|-
 
|align = "center" rowspan = "2"|'''Net Profit'''
 
|align = "center" rowspan = "2"|'''Net Profit'''
|2011: ¥7.38B / $92.25M
+
|2011: ¥ 7.38 B / $ 92.25 M
 
|-
 
|-
|2010: ¥47.76B / $597M
+
|2010: ¥ 47.76 B / $ 597 M
 
|-
 
|-
 
|align = "center" bgcolor = "#DBE5F1"|Net Profit Change
 
|align = "center" bgcolor = "#DBE5F1"|Net Profit Change
Line 83: Line 83:
 
|-
 
|-
 
|align = "center" rowspan = "2"|'''R&D Expenses'''
 
|align = "center" rowspan = "2"|'''R&D Expenses'''
|2011: ¥67.28B / $841M
+
|2011: ¥ 67.28 B / $ 841 M
 
|-
 
|-
|2010: ¥61.85B / $773M
+
|2010: ¥ 61.85 B / $ 773 M
 
|-
 
|-
 
|}
 
|}
Line 97: Line 97:
 
<br>
 
<br>
 
Source: SEC fillings
 
Source: SEC fillings
 +
 +
===Patents Held by Business group===
 +
 +
{|border="2" cellspacing="0" cellpadding="4" width="100%"
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Business Segment'''</font>
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Medical Systems'''</font>
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Life science & Industrial Systems'''</font>
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Imaging Systems'''</font>
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''R&D/Innovation'''</font>
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Total'''</font>
 +
|-
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Japan patents'''</font>
 +
|align = " center" bgcolor = "#DBE5F1"|2941
 +
|align = " center" bgcolor = "#DBE5F1"|1067
 +
|align = " center" bgcolor = "#DBE5F1"|2021
 +
|align = " center" bgcolor = "#DBE5F1"|1131
 +
|align = " center" bgcolor = "#DBE5F1"|'''7160'''
 +
|-
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''US patents'''</font>
 +
|align = " center" bgcolor = "#DBE5F1"|1059
 +
|align = " center" bgcolor = "#DBE5F1"|680
 +
|align = " center" bgcolor = "#DBE5F1"|1534
 +
|align = " center" bgcolor = "#DBE5F1"|974
 +
|align = " center" bgcolor = "#DBE5F1"|'''4247'''
 +
|-
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''China patents'''</font>
 +
|align = " center" bgcolor = "#DBE5F1"|405
 +
|align = " center" bgcolor = "#DBE5F1"|86
 +
|align = " center" bgcolor = "#DBE5F1"|444
 +
|align = " center" bgcolor = "#DBE5F1"|90
 +
|align = " center" bgcolor = "#DBE5F1"|'''1025'''
 +
|-
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Other patents'''</font>
 +
|align = " center" bgcolor = "#DBE5F1"|948
 +
|align = " center" bgcolor = "#DBE5F1"|249
 +
|align = " center" bgcolor = "#DBE5F1"|102
 +
|align = " center" bgcolor = "#DBE5F1"|165
 +
|align = " center" bgcolor = "#DBE5F1"|'''1464'''
 +
|-
 +
|bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Total'''</font>
 +
|align = " center" bgcolor = "#DBE5F1"|'''5353'''
 +
|align = " center" bgcolor = "#DBE5F1"|'''2082'''
 +
|align = " center" bgcolor = "#DBE5F1"|'''4101'''
 +
|align = " center" bgcolor = "#DBE5F1"|'''2360'''
 +
|align = " center" bgcolor = "#DBE5F1"|'''13896'''
 +
|-
 +
|}
 +
<br>
 +
 +
In Medical systems business, the company owns 39% of the total number of patents held by the company, with Japanese patents being the highest contributor to that.
  
 
==Business Overview==
 
==Business Overview==
Line 106: Line 156:
  
  
===Employee Distribution===
+
 
<br>
+
 
 
===Organisation Structure===
 
===Organisation Structure===
  
 
[[Image:OrgChart_Oympus.png|centre]]
 
[[Image:OrgChart_Oympus.png|centre]]
 
<br>
 
<br>
 +
 +
In April 2011, the company launched their regional headquarters for Asia and Oceania to coordinate regional strategy and facilitate business infrastructure development.<br>
 +
Source: Company website, Linkedin
 +
 
==Medical Systems Business==
 
==Medical Systems Business==
  
Line 123: Line 177:
 
Medical systems business has the following business lines:
 
Medical systems business has the following business lines:
 
* '''Endoscopes''' <br>Endoscopic video imaging systems, medical information systems, fiberscope systems, broncho endoscope systems, endoscopic ultrasound systems; ultrasound fiberscopes; ultrasound probes; ultrasound centers; ultrasound-guided needle puncture systems; cleaning, disinfecting and sterilization systems; medical treatment peripherals; ancillary products
 
* '''Endoscopes''' <br>Endoscopic video imaging systems, medical information systems, fiberscope systems, broncho endoscope systems, endoscopic ultrasound systems; ultrasound fiberscopes; ultrasound probes; ultrasound centers; ultrasound-guided needle puncture systems; cleaning, disinfecting and sterilization systems; medical treatment peripherals; ancillary products
* '''Endosurgery''' <br>Endoscopy products for gastroenterological surgery, thoracic surgery, urology, gynecology, orthopedic surgery, neurosurgery, cardiovascular surgery, anesthesiology and otolaryngology; treatment and surgical equipment; peripherals
+
* '''MIP''' includes surgical endoscopes and treatment equipments
* '''Endotherapy''' <br>Endotherapy products
+
** '''Endosurgery''' <br>Endoscopy products for gastroenterological surgery, thoracic surgery, urology, gynecology, orthopedic surgery, neurosurgery, cardiovascular surgery, anesthesiology and otolaryngology; treatment and surgical equipment; peripherals
 +
** '''Endotherapy''' <br>Endotherapy products
  
  
Line 130: Line 185:
 
===Revenue===
 
===Revenue===
 
Medical systems business is the biggest business segment of Olympus corporation:
 
Medical systems business is the biggest business segment of Olympus corporation:
* Net sales ration : 40% approx.
+
* Net sales ratio : 40% approx.
 
* Contribution to total corporate operating income :109% approx.  
 
* Contribution to total corporate operating income :109% approx.  
 
:(before corporate allocation of expenses)
 
:(before corporate allocation of expenses)
{|align="center"
+
<br>
|<gflash>900 600 http://dolcera.com/upload/files/Medical_Device_Segment.swf</gflash>
+
{|border="2" cellspacing="0" cellpadding="4" width="81%" align="center"
 +
|bgcolor = "#376091"|<font color="#FFFFFF">'''Metrics ( in Billion Yen)'''</font>
 +
|bgcolor = "#376091"|<font color="#FFFFFF">''' '''</font>
 +
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2009'''</font>
 +
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2010'''</font>
 +
|align = "right" bgcolor = "#376091"|<font color="#FFFFFF">'''2011'''</font>
 +
|-
 +
|align = "left" bgcolor = "#95B3D7" rowspan = "3"|'''Medical Systems'''
 +
|'''Domestic'''
 +
|align = "right"|76.2
 +
|align = "right"|75.1
 +
|align = "right"|79.4
 +
|-
 +
|'''Overseas'''
 +
|align = "right"|307.6
 +
|align = "right"|275.7
 +
|align = "right"|275.9
 +
|-
 +
|bgcolor = "#95B3D7"|'''Total'''
 +
|align = "right" bgcolor = "#95B3D7"|'''383.89'''
 +
|align = "right" bgcolor = "#95B3D7"|'''350.75'''
 +
|align = "right" bgcolor = "#95B3D7"|'''355.46'''
 +
|-
 +
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|Endoscopes
 +
|align = "center"|Domestic
 +
|align = "right"|44.6
 +
|align = "right"|40.9
 +
|align = "right"|43.8
 +
|-
 +
|align = "center"|Overseas
 +
|align = "right"|168.3
 +
|align = "right"|151
 +
|align = "right"|151.6
 +
|-
 +
|align = "center" bgcolor = "#DBE5F1"|'''Total'''
 +
|align = "right" bgcolor = "#DBE5F1"|'''212.9'''
 +
|align = "right" bgcolor = "#DBE5F1"|'''191.9'''
 +
|align = "right" bgcolor = "#DBE5F1"|'''195.5'''
 +
|-
 +
|align = "center" bgcolor = "#DBE5F1" rowspan = "3"|MIP
 +
|align = "center"|Domestic
 +
|align = "right"|31.6
 +
|align = "right"|34.2
 +
|align = "right"|35.6
 +
|-
 +
|align = "center"|Overseas
 +
|align = "right"|139.3
 +
|align = "right"|124.6
 +
|align = "right"|124.3
 +
|-
 +
|align = "center" bgcolor = "#DBE5F1"|'''Total'''
 +
|align = "right" bgcolor = "#DBE5F1"|'''170.9'''
 +
|align = "right" bgcolor = "#DBE5F1"|'''158.8'''
 +
|align = "right" bgcolor = "#DBE5F1"|'''159.9'''
 
|-
 
|-
 
|}
 
|}
 
<br>
 
<br>
Source: SEC fillings
 
<br>
 
<nowiki>*</nowiki> MIP includes surgical endoscopes and treatment equipments.
 
*Medical systems segment has over 14,000 employees
 
  
 
===Projections for FY 2012===
 
===Projections for FY 2012===
Line 147: Line 251:
 
<br>
 
<br>
  
* In endoscopes, new shipments of some products (Lucera) have ground to a halt, but the company expects to see a rebound in 2H. For the year as a whole it projects endoscope sales will be down 5% YoY.
+
* In endoscopes, new shipments of some products (Lucera) have ground to a halt, but the company expects to see a rebound in 2nd Half. For the year as a whole it projects endoscope sales will be down 5% YoY.
* The company estimates 1H sales in the medical systems division at JPY165bn (-6% YoY), and OP at JPY27bn; it projects 2H sales at JPY195bn (+8%) and OP at JPY43bn.
+
* The company estimates 1st Half sales in the medical systems division at JPY165bn (-6% YoY), and OP at JPY27bn; it projects 2nd Half sales at JPY195bn (+8%) and OP at JPY43bn.
 
* In the medical systems division, new product launches are planned for both surgical endoscopes and energy devices (treatment tools).
 
* In the medical systems division, new product launches are planned for both surgical endoscopes and energy devices (treatment tools).
 
* It projects sales of MIPs (surgical endoscopes, treatment equipment) at JPY180.5bn (+10% YoY). Sales in FY3/11 were flat YoY due mainly to the strength of the yen, but positive growth is expected this year.
 
* It projects sales of MIPs (surgical endoscopes, treatment equipment) at JPY180.5bn (+10% YoY). Sales in FY3/11 were flat YoY due mainly to the strength of the yen, but positive growth is expected this year.
* The company projects sales of gastrointestinal endoscopes at JPY164bn, -5% YoY, reflecting production setbacks in 1H.
+
* The company projects sales of gastrointestinal endoscopes at JPY164bn, -5% YoY, reflecting production setbacks in 1st Half.
 
* The earthquake’s impact has caused bottlenecks in purchasing of parts and materials for gastrointestinal endoscopes,leading to delays in product launches. In the latest telephone conference, the company offered no new information about timing. We believe there has been no real change from the company’s comments at the results briefing in May,and it remains to be seen whether the company will be able to launch its new products this fiscal year. The company’s FY3/12 earnings forecasts do not reflect any contribution from new products. Sales in the medical systems division got off to a slow start, falling short of projections in April-May.
 
* The earthquake’s impact has caused bottlenecks in purchasing of parts and materials for gastrointestinal endoscopes,leading to delays in product launches. In the latest telephone conference, the company offered no new information about timing. We believe there has been no real change from the company’s comments at the results briefing in May,and it remains to be seen whether the company will be able to launch its new products this fiscal year. The company’s FY3/12 earnings forecasts do not reflect any contribution from new products. Sales in the medical systems division got off to a slow start, falling short of projections in April-May.
 
<br>
 
<br>
  
===Geographic Presence==
+
===Geographic Presence===
 +
[[Image:Geo_olympus.PNG|center|1000px|thumb| Source: [http://www.olympus-global.com/ Olympus]]]
 +
<br>
 +
 
 +
===Corporate Strategic Plan===
 +
* Expand the endoscopic business base ( Gastrointestinal )
 +
** Gain a dominant market share and ensure profitability in the imaging field
 +
*** Early introduction and diffusion of next generation endoscope systems
 +
*** Establishment of a significant presence in emerging markets
 +
*** Diagnostic technology to promote early detection
 +
*** Endoscope technology to achieve definite diagnoses
 +
** Imaging technology for achieving early detection :Narrow Band Imaging (NBI)
 +
*** Acquisition of approval of insurance reimbursement for medical effects from early cancer detection using NBI ( in Japan)
 +
*** Initiative for standardization of NBI observation as diagnosis
 +
* Growth Drivers
 +
** Expansion of EndoTherapy field
 +
*** Introduce Visera Elite, a new integrated endoscopy video system
 +
*** Secure a 30% share of the global operating room imaging market in 2015
 +
*** Expand the lineup of differentiated products focused on minimally invasive surgical techniques
 +
*** Achieve the top share (30%) of the existing global endoscopy market in 2015. Also, secure top share of the Japanese market and further strengthen the sales structure
 +
** Expansion of Chinese and Asian market
 +
*** Introduce popularly prices models
 +
*** Expand the size of the market and share in such markets. Increase the number of endoscopists and improve their training.
  
 
==Endoscopes Business==
 
==Endoscopes Business==
Line 171: Line 297:
  
 
===Product Portfolio===
 
===Product Portfolio===
 
+
The company offers endoscopes in various specialties. The following is a comprehensive list of endoscopes ,according to specialty, that the company offers:<br>
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_ebus_bronchoscopes.asp EBUS Bronchoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_fiber_bronchoscopes.asp Fiber Optic Bronchoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_video_bronchoscopes.asp Video Bronchoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_capsulescopes.asp Capsule Endoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_choledochoscopes.asp Choledochoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_colonoscopes.asp Colonoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_duodenoscopes.asp Duodenoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_echoendoscopes.asp Echoendoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_enteroscopes.asp Enteroscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_esophagoscopes.asp Esophagoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_gastroscopes.asp Gastroscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_laryngoscopes.asp Laryngoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_maf.asp Intubation Scopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_rhinolaryngoscopes.asp Rhinolaryngoscopes]
 +
* [http://www.olympusamerica.com/msg_section/msg_endoscopy_sigmoidoscopes.asp Sigmoidoscopes]
 
[[Image:prodcuts_olympus.PNG|center|frame| [http://www.olympus-global.com/en/ Olympus]]]
 
[[Image:prodcuts_olympus.PNG|center|frame| [http://www.olympus-global.com/en/ Olympus]]]
 
<br>
 
<br>
In the medical equipment market, growth in the inspection device field has been stagnant, although such therapeutic device fields as surgical and endotherapy devices have shown market growth and drawn attention for technological innovation.
 
<br>
 
* The Exera 2, the previous entry in the Exera series, used NBI technology to enable full-color endoscopy, allowing doctors to more easily recognize affected areas in their patients. This product thus addressed doctors’ needs in the area of visibility, and sales grew worldwide.
 
 
  
 
===Recent Developments===
 
===Recent Developments===
 
<br>
 
<br>
 
{|border="2" cellspacing="0" cellpadding="4" width="100%"
 
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''S.No.'''</font>
+
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''S.No'''</font>
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''Date'''</font>
+
|align = "center" bgcolor = "#4F81BD" width="10%"|<font color="#FFFFFF">'''Date'''</font>
 
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''News/Development'''</font>
 
|align = "center" bgcolor = "#4F81BD"|<font color="#FFFFFF">'''News/Development'''</font>
 
|-
 
|-
|align = "right"|1.
+
|align = "center"|1
|1st July 2011
+
|align = "center"|July 2011
 
|[http://www.olympus-global.com/en/news/2011b/nr110704spiruse.html Olympus Corporation to Acquire Spirus Medical, Inc., an endoscope insertion device manufacturer]
 
|[http://www.olympus-global.com/en/news/2011b/nr110704spiruse.html Olympus Corporation to Acquire Spirus Medical, Inc., an endoscope insertion device manufacturer]
 
|-
 
|-
|align = "right"|2.
+
|align = "center"|2
|26th May 2011
+
|align = "center"|May 2011
 
|[http://www.olympus-global.com/en/news/2011a/nr110526awarde.html Narrow Band Imaging (NBI) endoscopic technology, useful in early cancer detection, selected for the Prime Minister Prize at the 2011 National Commendation for Invention]
 
|[http://www.olympus-global.com/en/news/2011a/nr110526awarde.html Narrow Band Imaging (NBI) endoscopic technology, useful in early cancer detection, selected for the Prime Minister Prize at the 2011 National Commendation for Invention]
 
|-
 
|-
|align = "right"|3.
+
|align = "center"|3
|24th May 2011
+
|align = "center"|May 2011
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=851 Olympus ScopeGuide Receives FDA Clearance]
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=851 Olympus ScopeGuide Receives FDA Clearance]
 
|-
 
|-
|align = "right"|4.
+
|align = "center"|4
|6th April 2011
+
|align = "center"|April 2011
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=850 Olympus Names Luke Calcraft as President of Medical Systems Group in the Americas]
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=850 Olympus Names Luke Calcraft as President of Medical Systems Group in the Americas]
 
|-
 
|-
|align = "right"|5.
+
|align = "center"|5
|10th February 2011
+
|align = "center"|February 2011
 
|[http://www.olympus-global.com/en/news/2011a/nr110210corpe.html Olympus Names Michael C. Woodford to Serve as President]
 
|[http://www.olympus-global.com/en/news/2011a/nr110210corpe.html Olympus Names Michael C. Woodford to Serve as President]
 
|-
 
|-
|align = "right"|6.
+
|align = "center"|6
|25th October 2010
+
|align = "center"|October 2010
 
|[http://www.olympus-europa.com/corporate/1696_4717.htm Magnetically guided capsule endoscope system presented at UEGW in Barcelona]
 
|[http://www.olympus-europa.com/corporate/1696_4717.htm Magnetically guided capsule endoscope system presented at UEGW in Barcelona]
 
|-
 
|-
|align = "right"|7.
+
|align = "center"|7
|26th May 2010
+
|align = "center"|May 2010
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=762 Olympus Develops World’s Fastest, Most Compatible Endoscope Reprocessor]
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=762 Olympus Develops World’s Fastest, Most Compatible Endoscope Reprocessor]
 
|-
 
|-
|align = "right"|8.
+
|align = "center"|8
|30th April 2010
+
|align = "center"|April 2010
 
|[http://www.olympus-europa.com/corporate/1696_4246.htm Olympus Medical Systems Corporation and Siemens Healthcare announce collaborative development of advanced magnetically guided capsule endoscope system for intragastric observation]
 
|[http://www.olympus-europa.com/corporate/1696_4246.htm Olympus Medical Systems Corporation and Siemens Healthcare announce collaborative development of advanced magnetically guided capsule endoscope system for intragastric observation]
 
|-
 
|-
|align = "right"|9.
+
|align = "center"|9
|12th April 2010
+
|align = "center"|April 2010
 
|[http://www.olympus-global.com/en/news/2010a/nr100412omsiple.html Olympus Medical Systems India Private Limited established, would take care of Sales, marketing and service for medical equipment (endoscopes and related products, and surgical products, etc.)]
 
|[http://www.olympus-global.com/en/news/2010a/nr100412omsiple.html Olympus Medical Systems India Private Limited established, would take care of Sales, marketing and service for medical equipment (endoscopes and related products, and surgical products, etc.)]
 
|-
 
|-
|align = "right"|10.
+
|align = "center"|10
|24th February 2010
+
|align = "center"|February 2010
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=745 Olympus Introduces HDTV Gastroscope with Auxiliary Water Channel]
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=745 Olympus Introduces HDTV Gastroscope with Auxiliary Water Channel]
 
|-
 
|-
|align = "right"|11.
+
|align = "center"|11
|10th November 2009
+
|align = "center"|November 2009
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=719 Olympus Introduces World's Smallest GI Scope to Offer 4-Way Angulation and Narrow Band Imaging]
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=719 Olympus Introduces World's Smallest GI Scope to Offer 4-Way Angulation and Narrow Band Imaging]
 
|-
 
|-
|align = "right"|12.
+
|align = "center"|12
|23rd October 2009
+
|align = "center"|October 2009
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=713 Improved Endo Capsule Software Enhances Diagnostic Experience]
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=713 Improved Endo Capsule Software Enhances Diagnostic Experience]
 
|-
 
|-
|align = "right"|13.
+
|align = "center"|13
|16th February 2009
+
|align = "center"|February 2009
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=662 Olympus Introduces World’s First Combined Endoscopic Ultrasound Processor for Imaging and Treatment of Digestive and Pulmonary Diseases]
 
|[http://www.olympusamerica.com/corporate/corp_presscenter_headline.asp?pressNo=662 Olympus Introduces World’s First Combined Endoscopic Ultrasound Processor for Imaging and Treatment of Digestive and Pulmonary Diseases]
 
|-
 
|-
|align = "right"|14.
+
|align = "center"|14
|11th December 2008
+
|align = "center"|December 2008
 
|[http://www.olympus-europa.com/corporate/1696_3032.htm Olympus further enhances credentials by entering into exclusive sales and distribution partnership with market and technology leader Advanced Surgical Concepts]
 
|[http://www.olympus-europa.com/corporate/1696_3032.htm Olympus further enhances credentials by entering into exclusive sales and distribution partnership with market and technology leader Advanced Surgical Concepts]
 
|-
 
|-
|align = "right"|15.
+
|align = "center"|15
|17th November 2008
+
|align = "center"|November 2008
 
|[http://www.olympus-europa.com/corporate/1696_2774.htm Olympus Medical Systems Europa and BrainLAB Sign Sales and Marketing Cooperation Agreement]
 
|[http://www.olympus-europa.com/corporate/1696_2774.htm Olympus Medical Systems Europa and BrainLAB Sign Sales and Marketing Cooperation Agreement]
 
|-
 
|-
 
|}
 
|}
 
<br>
 
<br>
 +
 
==Gastrointestinal Endoscopes Business==
 
==Gastrointestinal Endoscopes Business==
  
Line 269: Line 407:
  
 
===Market Share===
 
===Market Share===
[[Image:Coshare.PNG|center|frame|Source: Espicom]]
+
[[Image:GIshare.PNG|center|frame|Source: Espicom]]
 
<br>
 
<br>
 
{|border="2" cellspacing="0" cellpadding="4" width="52%" align="center"
 
{|border="2" cellspacing="0" cellpadding="4" width="52%" align="center"
Line 355: Line 493:
 
* PolyLoop Ligating Loop: Proprietary ligating loop for prophylactic hemostasis
 
* PolyLoop Ligating Loop: Proprietary ligating loop for prophylactic hemostasis
 
* Biopsy Forceps: Specially designed to minimize damage to the enteroscope with it's stainless steel construction.
 
* Biopsy Forceps: Specially designed to minimize damage to the enteroscope with it's stainless steel construction.
 +
|-
 +
|align = "center" rowspan = "1" bgcolor = "#4F81BD"|'''Sigmoidoscopy'''
 +
|bgcolor = "#DBE5F1"|Endoscopic examination, therapy or surgery of the sigmoid flexure
 +
|[[Image:Sig.PNG|100px]]
 +
|
 +
* PCF-S: Easy-reach L/R adapter (MAJ-1072) improves control and comfort for smaller hands and has a soft insertion tube for easier insertion and improved patient comfort. It is compatible with CV-180, CV-160 and CV-140 video processors.
 +
* OSF-V60: 730mm working length gives access to the entire sigmoid colon. It has a  Slim, 11.3mm insertion tube provides excellent handling while reducing patient discomfort.
 +
* CF-Q160S: Superior image quality with large display size provides enhanced details throughout the image plane. When used in combination with the company's dedicated flushing pump and CV-160 video system center, a continuously clear view is ensured by a forward water jet that removes obstacles inside the colon at the touch of a switch on the scope.
 +
* OSF-4: 700mm working length facilitates complete insertion. Generous 3.2mm instrument channel accommodates a wide variety of accessories.
 
|-
 
|-
 
|}
 
|}
Line 361: Line 508:
  
 
===New Products===
 
===New Products===
 +
*'''Scope Guide:'''<br>[[Image:Scope.PNG|right|140px]] is an exclusive Olympus technology designed to provide a real-time 3D image of the shape and configuration of the colonoscope inside the body. ScopeGuide assists with finding the optimal location to apply abdominal pressure, easier, more confident scope insertion, and early loop identification. The use of ScopeGuide during colonoscopies may lead to less patient discomfort.<br> By seeing the shape of the entire scope as it moves through the body, ScopeGuide provides additional visual information that is particularly helpful during difficult colonoscopies. The endoscopist can evaluate the extent of looping and get a better sense of which rotational maneuvers will be required to straighten out various loop formations that can occur during colonoscopy.
 
* '''Evis Lucera Colono-Videoscope:''' It helps in reducing the burden on patients and improving performance for both the inspection and treatment of colorectal cancer through the incorporation of two new functions, namely, high flexibility and highly responsive control at the insertion site, while adopting a thinner scope.
 
* '''Evis Lucera Colono-Videoscope:''' It helps in reducing the burden on patients and improving performance for both the inspection and treatment of colorectal cancer through the incorporation of two new functions, namely, high flexibility and highly responsive control at the insertion site, while adopting a thinner scope.
 
* '''Evis Lucera Gastrointestinal Videoscope:''' This slim gastrointestinal videoscope can be inserted through the nasal tract or the mouth to realise high quality images and is suited for the examination of lesions in the upper digestive tract, for example, in the stomach.
 
* '''Evis Lucera Gastrointestinal Videoscope:''' This slim gastrointestinal videoscope can be inserted through the nasal tract or the mouth to realise high quality images and is suited for the examination of lesions in the upper digestive tract, for example, in the stomach.
Line 370: Line 518:
 
** 6 white LED lights always ensure a clear field of view  
 
** 6 white LED lights always ensure a clear field of view  
 
** Compact battery with energy efficient technology
 
** Compact battery with energy efficient technology
The company is developing technologies to expand the application of capsule endoscopes to the stomach and large bowel.
+
:The company is developing technologies to expand the application of capsule endoscopes to the stomach and large bowel.
 +
 
 
<br>
 
<br>
 
Source: Company website, SEC fillings
 
Source: Company website, SEC fillings

Latest revision as of 03:01, 20 September 2011

Company overview

OLYMPUS CORPORATION, a Japan-based manufacturer, mainly manufactures and sells medical products, life and industrial products, imaging products, information communication products and other products. The Company operates in five business segments.

  • Medical Systems: Manufacture and sale of medical endoscopes, surgical endoscopes, endoscope disposal equipment and ultrasonic endoscopes
  • Life and Industrial: Provides biological microscopes, industrial microscopes, endoscopes for industrial use and non-destructive testing equipment
  • Imaging: Manufacture and sale of digital cameras and voice recorders
  • Information Communication: Sale of mobile terminals, such as cellular phones
  • Others: Development of biomaterials and systems, industrial endoscopes, nondestructive inspection equipment, printers, mobile solutions and mobile contents services, the development and sale of package software, the sale of semiconductor-related equipment and electronic machines, as well as the development of systems


In August 2009, the Company disposed its analytical equipment business to its wholly owned subsidiary, which has been engaged in the manufacturing and sale of clinical laboratory examination equipment. In addition, the Company has sold the subsidiary to Beckman Coulter, Inc. on August 1, 2009. As a result, the Company holds no stake in the subsidiary.
As of March 31, 2011, the Company has 188 subsidiaries and 11 associated companies.

Key Facts

Established 1919
Headquarters Tokyo, Japan
Type Public Company
Website www.olympus-global.com
Regional involvement Worldwide
Business lines Manufacture and Sales of precision machinery and instruments
Employees 34,391
Medical System Business: 15,000 Approx.
Group Companies Approx. 180 Subsidiaries
Chairman & CEO Tsuyoshi Kikukawa
President & COO Michael C. Woodford
Consolidated Net Sales (2011) 847.1 Billion YEN


Key Financials

Olympus Corporation
Financial Year End March, 31st
Revenue 2011: ¥ 847.10 B / $ 10.58 B
2010: ¥ 883.08 B / $ 11.03 B
Revenue Change -4.07%
Operating Income 2011: ¥ 35.4 B / $ 442 M
2010: ¥ 60.1 B / $ 751 M
Operating Income Change -41.10%
Net Profit 2011: ¥ 7.38 B / $ 92.25 M
2010: ¥ 47.76 B / $ 597 M
Net Profit Change -84.45%
R&D Expenses 2011: ¥ 67.28 B / $ 841 M
2010: ¥ 61.85 B / $ 773 M


Revenue Distribution

This is supposed to be a flash animation. You'll need the flash plugin and a browser that supports it to view it.


Source: SEC fillings

Patents Held by Business group

Business Segment Medical Systems Life science & Industrial Systems Imaging Systems R&D/Innovation Total
Japan patents 2941 1067 2021 1131 7160
US patents 1059 680 1534 974 4247
China patents 405 86 444 90 1025
Other patents 948 249 102 165 1464
Total 5353 2082 4101 2360 13896


In Medical systems business, the company owns 39% of the total number of patents held by the company, with Japanese patents being the highest contributor to that.

Business Overview

Business lines

The company operates under the following business lines:

Business lines.PNG



Organisation Structure

OrgChart Oympus.png


In April 2011, the company launched their regional headquarters for Asia and Oceania to coordinate regional strategy and facilitate business infrastructure development.
Source: Company website, Linkedin

Medical Systems Business

The Medical Systems Business covers gastrointestinal endoscopes, surgical endoscopes, endotherapy devices, endoscopic ultrasound systems and medical information systems.
With an approximately 70% share, the Olympus group has secured a leading position in the global Gastrointestinal endoscopy market. Working to expand diagnostic coverage beyond the digestive system, the group is developing new equipment and new techniques ranging from diagnosis through treatment.
It's current research focus is on both minimally invasive treatment technology that reduces the burden on patients and product usability, for example, enhanced performance and functions to benefit doctors and technicians. The group's flagship products are equipped with a high-resolution endoscopic system and Narrow Band Imaging technology so that they can also support cancer diagnosis and treatment.

Medical systems business has the following business lines:

  • Endoscopes
    Endoscopic video imaging systems, medical information systems, fiberscope systems, broncho endoscope systems, endoscopic ultrasound systems; ultrasound fiberscopes; ultrasound probes; ultrasound centers; ultrasound-guided needle puncture systems; cleaning, disinfecting and sterilization systems; medical treatment peripherals; ancillary products
  • MIP includes surgical endoscopes and treatment equipments
    • Endosurgery
      Endoscopy products for gastroenterological surgery, thoracic surgery, urology, gynecology, orthopedic surgery, neurosurgery, cardiovascular surgery, anesthesiology and otolaryngology; treatment and surgical equipment; peripherals
    • Endotherapy
      Endotherapy products


Revenue

Medical systems business is the biggest business segment of Olympus corporation:

  • Net sales ratio : 40% approx.
  • Contribution to total corporate operating income :109% approx.
(before corporate allocation of expenses)


Metrics ( in Billion Yen) 2009 2010 2011
Medical Systems Domestic 76.2 75.1 79.4
Overseas 307.6 275.7 275.9
Total 383.89 350.75 355.46
Endoscopes Domestic 44.6 40.9 43.8
Overseas 168.3 151 151.6
Total 212.9 191.9 195.5
MIP Domestic 31.6 34.2 35.6
Overseas 139.3 124.6 124.3
Total 170.9 158.8 159.9


Projections for FY 2012

Quarter 3

  • In endoscopes, new shipments of some products (Lucera) have ground to a halt, but the company expects to see a rebound in 2nd Half. For the year as a whole it projects endoscope sales will be down 5% YoY.
  • The company estimates 1st Half sales in the medical systems division at JPY165bn (-6% YoY), and OP at JPY27bn; it projects 2nd Half sales at JPY195bn (+8%) and OP at JPY43bn.
  • In the medical systems division, new product launches are planned for both surgical endoscopes and energy devices (treatment tools).
  • It projects sales of MIPs (surgical endoscopes, treatment equipment) at JPY180.5bn (+10% YoY). Sales in FY3/11 were flat YoY due mainly to the strength of the yen, but positive growth is expected this year.
  • The company projects sales of gastrointestinal endoscopes at JPY164bn, -5% YoY, reflecting production setbacks in 1st Half.
  • The earthquake’s impact has caused bottlenecks in purchasing of parts and materials for gastrointestinal endoscopes,leading to delays in product launches. In the latest telephone conference, the company offered no new information about timing. We believe there has been no real change from the company’s comments at the results briefing in May,and it remains to be seen whether the company will be able to launch its new products this fiscal year. The company’s FY3/12 earnings forecasts do not reflect any contribution from new products. Sales in the medical systems division got off to a slow start, falling short of projections in April-May.


Geographic Presence

Source: Olympus


Corporate Strategic Plan

  • Expand the endoscopic business base ( Gastrointestinal )
    • Gain a dominant market share and ensure profitability in the imaging field
      • Early introduction and diffusion of next generation endoscope systems
      • Establishment of a significant presence in emerging markets
      • Diagnostic technology to promote early detection
      • Endoscope technology to achieve definite diagnoses
    • Imaging technology for achieving early detection :Narrow Band Imaging (NBI)
      • Acquisition of approval of insurance reimbursement for medical effects from early cancer detection using NBI ( in Japan)
      • Initiative for standardization of NBI observation as diagnosis
  • Growth Drivers
    • Expansion of EndoTherapy field
      • Introduce Visera Elite, a new integrated endoscopy video system
      • Secure a 30% share of the global operating room imaging market in 2015
      • Expand the lineup of differentiated products focused on minimally invasive surgical techniques
      • Achieve the top share (30%) of the existing global endoscopy market in 2015. Also, secure top share of the Japanese market and further strengthen the sales structure
    • Expansion of Chinese and Asian market
      • Introduce popularly prices models
      • Expand the size of the market and share in such markets. Increase the number of endoscopists and improve their training.

Endoscopes Business

Market Share

Source: Espicom


The worldwide endoscopy market (comprising laparoscopy, gastro-intestinal, visualisation, arthroscopy and urology products, rigid and flexible scopes, implants, surgical and other instruments) was worth approximately US$21.3 billion in 2009. Olympus’ share of this market was estimated to be 18%($3.834B), behind market leader Johnson & Johnson with an approximate 21% market share. In third place was Covidien (13%), followed by Boston Scientific (7%), Stryker (4%), Smith & Nephew (4%) and Karl Storz (4%).

Product Portfolio

The company offers endoscopes in various specialties. The following is a comprehensive list of endoscopes ,according to specialty, that the company offers:


Recent Developments


S.No Date News/Development
1 July 2011 Olympus Corporation to Acquire Spirus Medical, Inc., an endoscope insertion device manufacturer
2 May 2011 Narrow Band Imaging (NBI) endoscopic technology, useful in early cancer detection, selected for the Prime Minister Prize at the 2011 National Commendation for Invention
3 May 2011 Olympus ScopeGuide Receives FDA Clearance
4 April 2011 Olympus Names Luke Calcraft as President of Medical Systems Group in the Americas
5 February 2011 Olympus Names Michael C. Woodford to Serve as President
6 October 2010 Magnetically guided capsule endoscope system presented at UEGW in Barcelona
7 May 2010 Olympus Develops World’s Fastest, Most Compatible Endoscope Reprocessor
8 April 2010 Olympus Medical Systems Corporation and Siemens Healthcare announce collaborative development of advanced magnetically guided capsule endoscope system for intragastric observation
9 April 2010 Olympus Medical Systems India Private Limited established, would take care of Sales, marketing and service for medical equipment (endoscopes and related products, and surgical products, etc.)
10 February 2010 Olympus Introduces HDTV Gastroscope with Auxiliary Water Channel
11 November 2009 Olympus Introduces World's Smallest GI Scope to Offer 4-Way Angulation and Narrow Band Imaging
12 October 2009 Improved Endo Capsule Software Enhances Diagnostic Experience
13 February 2009 Olympus Introduces World’s First Combined Endoscopic Ultrasound Processor for Imaging and Treatment of Digestive and Pulmonary Diseases
14 December 2008 Olympus further enhances credentials by entering into exclusive sales and distribution partnership with market and technology leader Advanced Surgical Concepts
15 November 2008 Olympus Medical Systems Europa and BrainLAB Sign Sales and Marketing Cooperation Agreement


Gastrointestinal Endoscopes Business

With an approximately 70% global market share for gastrointestinal endoscopes and an established position at the medical vanguard, Olympus maintains its passion for advancing technologies in response to doctors' needs

Diagnosis and Treatment using Gastrointestinal Endoscopy

Diagnosis

  • Biopsy
  • Cytodiagnosis
  • Staining


Treatment

  • Cancer (esophageal, stomach, colon, etc.)
  • Varcies (esophageal)
  • Foreign object retrieval ( esophagus, stomach)
  • Hemostasis (stomach)
  • Ployps (stomach, colon)
  • Gallstones, bile duct stenosis (duodenum)

Market Share

Source: Espicom


Company ( in Billion Yen) 2009 2010 2011
Olympus 212.89 191.94 195.45
FujiFilm HD 26.98 25.00 27.00
Hoya 48.87 47.00 45.00

Products Offered


Speciality Details Picture Products
Gastroscopy Endoscopic examination, therapy or surgery of the interior of the stomach. Gastroscope2.PNG Gastroscope.PNG Gastroscope1.PNG
  • GIF-H180J: Enables one to perform upper gastrointestinal endoscopy utilising the latest auxiliary water function and the sharpest possible image quality provided by High-resolution HDTV images featuring Narrow Band Imaging™ (NBI) and Close Focus
  • GIF-H180: Delivers the best possible image quality for upper GI. High-resolution HDTV images in combination with Narrow Band Imaging (NBI) and Close Focus functionality
  • GIF-XP180N: Ultra-slim upper gastrointestinal endoscopy with four-way angulation, NBI compatibility and a 5.5mm diameter distal end and insertion tube
  • GIF-Q180: Features a short bending section as well as a reduced bending radius. Manoeuvrability and observation especially in the cardia region are enhanced.
  • GIF-N180: The entire insertion tube measures just 4.9mm in diameter, resulting in improved insertability and the option for transnasal insertion in nearly 100 % of cases.
  • GIF-Q165: Clear, sharp high-quality images in a large-size display and slim, 9.2 mm diameter distal end insertion tuber with wide 140° feild of view
  • GIF-2T160: Two-channel endoscope for a variety of therapeutic applications
  • GIF-XTQ160: Endoscope with powerful suction capabilities
  • GIF-1TQ160: Endoscope with extended instrumentation capabilities
  • GIF-Q160Z: Powerful 115 times magnification for detailed examination of the mucous surface
Duodenoscopy Endoscopic examination, therapy or surgery of the luminal surface of the duodenum TJF-Q180V.PNG TJF-160VR.PNG
  • TJFQ180V: Provides critical visual feedback to enhance clinical decision making. In addition, a completely redesigned forceps elevator offers doctors the control needed when locking various sizes of guidewire. The unique dual locking function sets a new standard for ease-of-use and security during instrument exchange.
  • TJF-160VR: Innovative V Groove forcep elevator offers reliable duodenoscopic treatment capability in combination with dedicated V-System ERCP devices
  • TJF-145: Excellent treatment capability with extra-large 4.2mm channel - perfect for a wide range of endo-therapy accessories including stents.
  • JF-140R: Facilitates introduction and manipulation of EndoTherapy accessories (for example papillotomes and ERCP catheters). The removable distal cap makes it possible to have access to all sides of the forceps elevator which can consequently be easily and quickly cleaned.
Colonoscopy Endoscopic examination, therapy or surgery of the luminal surface of the colon. CF-180AI.PNG CQ-180AI.PNG CF-Q160DI.PNG
  • CF-H180AI/L: High-resolution HDTV images combined with the widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.
  • CF-Q180AI/L: The widest field of view ever available in a colonoscope: 170° lets you look even behind the folds potentially decreasing the miss-rate and improving orientation inside the colon.
  • CF-Q160DI/L: ScopeGuide is a new Olympus product, which displays the shape and position of a colonoscope in real time throughout the examination without the use of x-rays. It based on magnetic fields generated by small coils build inside this endoscope and picked up by the antenna of ScopeGuide's main unit. From this data, the computer reconstructs a schematic picture of endoscope on the display.
  • PCF-H180AI/L: Extra-slim colonoscope featuring outstanding high-resolution HDTV imaging and adjustable insertion characteristics
  • CF-Q165I/L: Versatile colonoscope combining high image quality, large-size display and powerful treatment capability.
  • CF-1T140I/L: For use in both therapeutic procedures and routine examinations, offers “graduated flexibility” for ease of insertion, and greater operational control and torque transmission to the distal end.
  • CF-2T160I/L: Two-channel therapeutic capabilities
  • CF-Q160ZI/L: Precision design that enables lens movement fully controlled via a connected magnification controller, which also provides foot switch operation. Powerful 150 times zoom magnification delivers detailed close-ups
Proctoscopy Endoscopic examination, therapy or surgery of the luminal surface of the rectum. Procto.PNG
  • Rectal Diagnostic System: a complete line-up of instruments for rectoscopy, which have been especially designed for the diagnosis of possible disorders in the rectal region. Highest functionality combined with long-term durability distinguishes these instruments at reasonable investment costs.
  • Transanal Endoscopic Microsurgery System: a versatile line up of transparent tubes enable clear inspection of the affected area. Access to a lesion is made easier by a "side window sheath". Fully compatible with standard VISERA equipment.
Enteroscopy Endoscopy of the small intestines accomplished while advancing the endoscope into the intestines from the stomach Enteroscope1.png Enteroscope2.png
  • QuickClip2 Hemostatic Clip: Rotatable function provides better targeting capability . It's 9 mm clip opening is ideal for targeting lesions in the tight confines of the small bowel
  • Injector Force Max Injection Needle: Kink-resistant sheath improves procedure efficiency and limits the occurrence of kinking in the depths of the small bowel.
  • BiCOAG: Bipolar spiral tip allows effective coagulation at virtually any angle and centrally located flushing port allows for easy irrigation
  • PolyLoop Ligating Loop: Proprietary ligating loop for prophylactic hemostasis
  • Biopsy Forceps: Specially designed to minimize damage to the enteroscope with it's stainless steel construction.
Sigmoidoscopy Endoscopic examination, therapy or surgery of the sigmoid flexure Sig.PNG
  • PCF-S: Easy-reach L/R adapter (MAJ-1072) improves control and comfort for smaller hands and has a soft insertion tube for easier insertion and improved patient comfort. It is compatible with CV-180, CV-160 and CV-140 video processors.
  • OSF-V60: 730mm working length gives access to the entire sigmoid colon. It has a Slim, 11.3mm insertion tube provides excellent handling while reducing patient discomfort.
  • CF-Q160S: Superior image quality with large display size provides enhanced details throughout the image plane. When used in combination with the company's dedicated flushing pump and CV-160 video system center, a continuously clear view is ensured by a forward water jet that removes obstacles inside the colon at the touch of a switch on the scope.
  • OSF-4: 700mm working length facilitates complete insertion. Generous 3.2mm instrument channel accommodates a wide variety of accessories.


Source: Company website

New Products

  • Scope Guide:
    Scope.PNG
    is an exclusive Olympus technology designed to provide a real-time 3D image of the shape and configuration of the colonoscope inside the body. ScopeGuide assists with finding the optimal location to apply abdominal pressure, easier, more confident scope insertion, and early loop identification. The use of ScopeGuide during colonoscopies may lead to less patient discomfort.
    By seeing the shape of the entire scope as it moves through the body, ScopeGuide provides additional visual information that is particularly helpful during difficult colonoscopies. The endoscopist can evaluate the extent of looping and get a better sense of which rotational maneuvers will be required to straighten out various loop formations that can occur during colonoscopy.
  • Evis Lucera Colono-Videoscope: It helps in reducing the burden on patients and improving performance for both the inspection and treatment of colorectal cancer through the incorporation of two new functions, namely, high flexibility and highly responsive control at the insertion site, while adopting a thinner scope.
  • Evis Lucera Gastrointestinal Videoscope: This slim gastrointestinal videoscope can be inserted through the nasal tract or the mouth to realise high quality images and is suited for the examination of lesions in the upper digestive tract, for example, in the stomach.
  • Capsule Endoscopes:
    Capsule.png
    They are non-invasive, endoscopic imaging by use of VIDEO CAPSULE ENDOSCOPES to perform examination of the gastrointestinal tract, especially the small bowel. After being introduced in 2007, they have become a revolution. High-resolution imaging, real-time viewing, ease of use and proprietary hard and software make EndoCapsule a comprehensive and powerful system - redefining capsule endoscopy.
    One has to simply swallow the Endo capsule, a pill sized (11mm in external diameter and 26mm in length) capsule equipped with a tiny camera and lights, allows pictures to be taken of the entire small bowel. Endo capsule delivers high resolution images equivalent to those provided by endoscopes. EndoCapsule displays a clear and bright field of view for the fine observation of a variety of small bowel abnormalities.
    The Real Time Viewer enables the physician to test the proper functionality before the procedure and to confirm the location of the capsule in the GI tract during the process. In addition it is now possible to check whether and when the capsule has left the stomach.
    Product Details:
    Capsule1.png
    • Supersensitive CCD
    • Ultra compact lens
    • Automatic Brightness Control adjusts illumination to maintain optimal imaging
    • A wide depth of field provides superior observation
    • 6 white LED lights always ensure a clear field of view
    • Compact battery with energy efficient technology
The company is developing technologies to expand the application of capsule endoscopes to the stomach and large bowel.


Source: Company website, SEC fillings